Introduction {#sec1}
============

Immunization is one of the most successful and cost-effective public health interventions to prevent infections. According to the World Health Organization, vaccinations currently prevent between 2 and 3 million deaths every year. Despite this success, much development work is still needed to provide effective vaccines for populations with impaired immune function (pediatric and elderly populations), prevent or treat global diseases where no effective vaccine exists (human immunodeficiency virus, tuberculosis), and provide effective solutions for newly emerging pathogens such as Zika and Chikungunya viruses. The effectiveness of vaccines can be improved using adjuvants to enhance, accelerate, and/or prolong a specific immune response. Despite many years of research and development, few adjuvants are currently approved for human use. Alum,^[@ref1]^ the oil-in-water emulsions MF59^[@ref2]^ and AS03,^[@ref3]^ monophosphoryl lipid A,^[@ref4]^ AS01,^[@ref5]^ AS04,^[@ref6]^ CpG,^[@ref7]^ and virosomes^[@ref8]^ have been approved in Europe and/or the USA and have an acceptable safety profile and are considered effective. The water-in-oil emulsion Montanide ISA51^[@ref9]^ and the synthetic TLR4 agonist CRX-529^[@ref10]^ have also been approved in Cuba and Argentina, respectively. While these adjuvants are effective at increasing humoral immunity, adjuvants capable of eliciting durable cell-mediated immune responses are still needed.

Pattern-recognition receptor (PRR) ligands have been extensively investigated as vaccine adjuvants^[@ref11],[@ref12]^ because of their critical role in innate immunity and their ability to shape downstream adaptive immunity. PRRs are differentially localized on many cell types and act as sentinels to recognize a wide range of exogenous pathogen-associated molecular patterns (PAMPs) and endogenous damage-associated molecular patterns. Among the five major families of PRRs^[@ref13]^ characterized so far, Toll-like receptors (TLRs), the first PRRs to be discovered,^[@ref14]^ are the most widely investigated. Each TLR is composed of an ectodomain with leucine-rich repeats that mediate PAMP recognition, a transmembrane domain, and a cytoplasmic Toll/IL-1 receptor domain that initiates downstream signaling. Upon the recognition of PAMPs, TLRs induce a signal transduction cascade leading to the production of cytokines and the activation and recruitment of cellular mediators, critical for initiating innate and adaptive immune responses. Among the 10 known TLRs in humans, TLR1, 2, 4, 5, and 6 recognize bacterial components, while TLR3, 7, and 8 and TLR9 detect viral RNA and unmethylated DNA, respectively.^[@ref15]^ Among the different TLRs, TLR7 and TLR8, which recognize uridine- and/or guanosine-rich viral ssRNA, are broadly expressed on dendritic cells (DCs) and other antigen-presenting cells, making TLR7/8 agonists especially valuable for the development of vaccine adjuvants.^[@ref16]^ Human TLR7 is mainly expressed on plasmacytoid DC and B cells and its activation induces IFNα via the IRF7 pathway^[@ref17]^ and proinflammatory cytokines via the NFκB pathway. Human TLR8 is mainly expressed on monocytes, macrophages, neutrophils, and conventional DCs, including a small population of BDCA3^+^ cells shown to be very effective at cross-presenting exogenous antigens to CD8 T cells,^[@ref18],[@ref19]^ and its activation induces proinflammatory cytokines such as TNFα and IL-12p70. While some TLR7/8 agonists are effective vaccine adjuvants in vivo,^[@ref16],[@ref20]−[@ref22]^ other vaccine studies have shown a lack of adjuvant activity with some small-molecule TLR7/8 agonists.^[@ref16],[@ref23],[@ref24]^ Additionally, conventional vaccination routes (subcutaneous, intramuscular, and intranasal), and oral and topical preparations of small-molecule TLR7/8 agonists can lead to serious side effects due to systemic cytokine distribution, and some clinical trials have been suspended over safety concerns.^[@ref25]−[@ref29]^ Consequently, the development of safer and more effective TLR7/8 agonists as vaccine adjuvants is needed.

Several small-molecule TLR7/8 agonists mimicking the natural viral ssRNA ligands have been identified,^[@ref30]−[@ref32]^ including 1*H*-imidazo\[4,5-*c*\]quinolines^[@ref33]^ (Resiquimod, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) and 8-oxoadenines^[@ref34]^ (SM360320, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Numerous reports on the structure--activity relationship (SAR) of 8-oxoadenines substituted at the 9-position with arylmethyl and heteroarylmethyl groups have been published.^[@ref35]−[@ref42]^

![Representative structures of imidazoquinolines and oxoadenines, and oxoadenines **1**--**8**.](ao9b02138_0001){#fig1}

Except for a few oxoadenines substituted at the 9-position with cycloalkyl groups and reported as inducing weak or diminished IFN induction,^[@ref34],[@ref38]^ no systematic studies had been performed on oxoadenines substituted with heterocyclic groups until a recent publication describing the development of a highly potent oxoadenine TLR7 agonist for the treatment of asthma (GSK2245035, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref43]^ This work investigated the effect of N- and O-heterocycles at the N-9-position of the oxoadenine scaffold on IFNα and TNFα induction. Except for two derivatives, the nitrogen atom of the N-heterocycle was linked to the oxoadenine or substituted with an alkyl group. As reported herein, we synthesized and evaluated N-heterocyclic oxoadenines of general structures **1**--**8** ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) containing an unsubstituted amine or hydroxyl group. Substitution of the aromatic amino group abolishes IFN induction,^[@ref44]^ whereas the NH (or OH) group in oxoadenines **1**--**8** provides an alternative option for subsequent N- or O-derivatization and conjugation. Conjugation of TLR7/8 agonists to proteins,^[@ref23],[@ref45]−[@ref49]^ peptides,^[@ref50]^ and other molecules^[@ref51],[@ref52]^ has been used to improve immune responses and decrease the toxicity of the TLR7/8 agonists. Furthermore, since TLR7 and TLR8 are located in endosomal/lysosomal compartments,^[@ref53]^ cellular uptake is a prerequisite for activation by TLR7/8 ligands. Thus, there is considerable interest in strategies that will increase the penetration of the TLR7/8 ligand into DCs and other immune cells while concomitantly reducing systemic toxicity. Lipid conjugation of nucleoside drugs including TLR7/8 agonists^[@ref54],[@ref55]^ is one strategy known to facilitate endocytosis and decrease toxic side effects. Such nucleolipids can be incorporated into liposomes and other biodegradable nanoparticles to help protect the drug from degradation, target the TLR7/8 ligand to DCs, and further reduce toxicity through a depot effect.^[@ref56]^

In the course of our own SAR program aimed at developing safe and effective TLR7/8 agonists as vaccine adjuvants, we previously synthesized and evaluated a series of seven new 8-oxoadenines **1** ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) substituted at the N-9 with a 4-piperidinylalkyl moiety (*n* = 0--6).^[@ref57]^ We demonstrated that TLR7/8 selectivity/potency and cytokine induction could be modulated by varying the length of the alkyl linker. In this paper, we expanded upon our initial SAR study in the 2-butoxy-oxoadenine series by investigating the effect of different N-heterocycles (azetidine, pyrrolidine, piperidine, and piperazine), N-heterocycle chirality, and substitution in combination with different linker lengths on TLR7/8 potency and receptor selectivity and on cytokine (IFNα and TNFα) induction from adult human peripheral blood mononuclear cells (hPBMCs). The goal of this study was to optimize the substituent at the N-9-position of the oxoadenine scaffold and select lead TLR7-selective and TLR7/8 active oxoadenines for further optimization of the substituent at the 2-position and subsequent lipidation to generate new and safe TLR7/8 agonists.

Results and Discussion {#sec2}
======================

Chemistry {#sec2.1}
---------

8-Oxoadenines **2**--**4** and **5**([@ref58]) were synthesized in two steps by alkylation of the common advanced intermediate 2-*n*-butoxy-8-methoxyadenine **9** with the requisite *N*-*t*-butoxycarbonyl (Boc)-protected alkyl bromides or iodide (**11a**), either purchased commercially or prepared from the corresponding alcohols using Appel conditions (Ph~3~P/CBr~4~; **12c**, **12f**), and acidic deprotection ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}), as previously described.^[@ref57]^ The common advanced intermediate **9** was prepared^[@ref57]^ in six steps from commercially available 2,6-dichloropurine. Alkylation of **9** with alkyl bromides led predominantly to the *N*-9-alkylated product (based on numerous reports in the literature indicating that alkylation of 6-amino-adenines with alkyl/aryl bromides in the presence of potassium carbonate predominantly leads to the *N*-9 regioisomer^[@ref36],[@ref38]−[@ref40],[@ref43],[@ref59]^and to a lesser extent to the *N*-7-regioisomer). The formation of up to 30% of the *N*-7-regioisomer was also observed. In most cases, the *N*-7-regioisomer was removed by chromatography after the alkylation step or after the acidic deprotection step (for compounds **2a,b**, **4a**, **4d,e**). The *N*-substituted 4-piperidinylmethyl oxoadenines **6a**--**d** were prepared in two steps by alkylation of the 4-piperidinylmethyl oxoadenine **1a**([@ref57]) with the corresponding *O*-*t*-butyldimethylsilyl (TBS)- or *N*-Boc-protected alkyl bromides, and acidic deprotection ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}).

![Synthesis of Oxoadenines **3**--**5**\
Reagents and conditions: (i) K~2~CO~3~, Br(CH~2~)*~n~*NHBoc, dimethylformamide (DMF), 50 °C, 16 h, 56--70%; (ii) 4 N HCl/dioxane, CH~3~OH, rt, 1 h, 50--86%; (iii) K~2~CO~3~, DMF, 50 °C, 16 h, 38--93%.](ao9b02138_0002){#sch1}

![Synthesis of Oxoadenines **6a**--**d**\
Reagents and conditions: (i) K~2~CO~3~, Br(CH~2~)pR, DMF, 50 °C, 2--7 h, 67--83%; (ii) 4 N HCl/dioxane, CH~3~OH, rt, 1 h, 74--100%.](ao9b02138_0003){#sch2}

The piperazinylethyl oxoadenine **7a** was prepared by alkylation of **9** with the requisite *N*-Boc-protected piperazinylethyl bromide followed by acidic deprotection ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). Synthesis of the piperazinylbutyl oxoadenine **7b** by alkylation of **9** with *N*-Boc-protected piperazinylbutyl bromide could not be attempted because bromination (Appel conditions) of *N*-Boc-protected piperazinylbutyl alcohol (prepared in a 48% yield by alkylation of *N*-Boc-piperazine with 1-bromo-4-butanol) failed. Instead, the synthesis of **7b** was accomplished in three steps by first introducing the butyl linker in **9** by alkylation with 1-bromo-4-chlorobutane, followed by alkylation of the resulting chloro-adenine **15** with *N*-Boc-protected piperazine, and subsequent acidic deprotection ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). In the same manner, oxoadenines **8a,b** were prepared in three steps by alkylation of **9** with 1,2-dibromoethane followed by alkylation of the resulting bromoadenine **17** with the requisite 4-*N*-Boc-protected- or 4-hydroxy-piperidine and acidic deprotection ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}).

![Synthesis of Oxoadenines **7** and **8**\
Reagents and conditions: (i) K~2~CO~3~, DMF, 50 °C, 16--120 h, 48--96%; (ii) 4 N HCl/dioxane, CH~3~OH, rt, 1 h, 77--98%.](ao9b02138_0004){#sch3}

Biological Activity {#sec2.2}
-------------------

Oxoadenines **1**--**8** were assessed for human (h) TLR7 and TLR8 specificity and potency in cell lines and primary human cells and compared to the known benchmarks imidazoquinoline R848 (Resiquimod, a dual TLR7/8 agonist) and Sumitomo oxoadenine SM360320 (TLR7 agonist). Human TLR7/8 potency and specificity were evaluated using HEK293 cells stably transfected with either hTLR7 or hTLR8 and the NFκB SEAP (secreted embryonic alkaline phosphatase) reporter. This assay measures NFκB-mediated SEAP production following TLR7- or TLR8-specific activation. The HEK reporter assay only measures activation through the NFκB pathway and thus the IRF7 pathway activation by TLR7 agonists is not detected in this assay. Of note, our previously published report with some of the compounds described herein used in-house derived stably transfected HEK293 cells.^[@ref57]^ The current study uses commercially obtained HEK293-hTLR7 and hTLR8 NFkB-SEAP reporter cells from Novus Biologicals (Littleton, CO) and Invivogen (San Diego, CA), respectively, resulting in some changes in EC~50~ values and in TLR7/8 specificity from the previously published findings. Freshly isolated primary human PBMCs were used to confirm HEK assay responses and assess the cytokine induction (IFNα and TNFα) ability of oxoadenines **1**--**8** and benchmarks. We first focused our efforts on the synthesis and evaluation of unsubstituted N-heterocyclic oxoadenine derivatives **2**--**5** to investigate the effect of linker length (0--4 carbons), ring chirality, and ring size (4- to 6-member ring) on both hTLR7 and hTLR8 activity and cytokine induction.

### Carbon Linker Length {#sec2.2.1}

Regardless of the N-heterocycle size, hTLR7 activity and potency increased with increasing linker length in the HEK293-hTLR7 NFκB reporter assay ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)). Going from no linker to 1-carbon linker in the azetidine (**3a** to **3b**) and pyrrolidine (**4a**,**d** to **4b**,**e**) series increased TLR7 potency by 15- to 28-fold, and adding a second carbon (**3c**, **4c**, and **4f**) further increased TLR7 potency by 2- to 5-fold ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). In the piperidine series (**1**), this effect was more pronounced with a 22-fold potency increase between the 1C- and 2C-linker oxoadenines (**1a** and **1b**) and another 1.4-fold increase between the 2C- and 4C-linker oxoadenines (**1b** and **1c**). We have previously reported that the 0C-linker derivative in the piperidine series was inactive and observed a similar trend in potency increase with linker length.^[@ref57]^ This observation held true in the aminoalkyl series with a 158-fold increase in potency between the aminoethyl and aminobutyl oxoadenines **2a** and **2b** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)).

###### Chemical Structures, TLR7 and TLR8 Activities, and Cytokine Induction of 8-Oxoadenines

![](ao9b02138_0005){#fx1}

![](ao9b02138_0006){#fx2}

PL (peak level) at 10 μM.

PL at 2 μM. MEC (minimum effective concentration; lowest dose tested that induced cytokine), and PL and PC (peak concentration) are from one out of three donors. TLR7 and TLR8 EC~50~s are the mean values and standard deviation of three independent experiments.

The aminobutyl (**2b**), piperidinyl-ethyl (**1b**) and -butyl (**1c**), and pyrrolidinylethyl (**4c**) oxoadenines were as potent or more potent than the imidazoquinoline R848 and oxoadenine SM360320 benchmarks. As expected, oxoadenines **1**--**4** were weaker hTLR8 agonists with EC~50~ \>100 μM ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)), except for the aminobutyl oxoadenine **2b** displaying an EC~50~ of 59 μM in the HEK293-hTLR8 NFκB reporter assay. A trend toward higher hTLR8 activity for the 1C-linker (**1a**, **3b**, and **4e**) was observed.

Regardless of the N-heterocycle, the minimum effective concentration (MEC) for IFNα induction decreased with increasing linker length ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)), although the peak concentration (PC) and level (PL) of IFNα did not correlate with the MEC values ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). We^[@ref57]^ and others^[@ref43]^ have previously shown optimal IFNα induction from 8-oxoadenines bearing 4- to 6-carbon linkers at the N-9-position. Interestingly, although the ethyl and butyl derivatives (**1b,c**, **3c**, **4c**, and **4f**,) were more potent IFNα inducers (lower MEC), the methyl derivatives (**1a**, **3b**, **4b**, and **4e**) induced higher IFNα peak levels. Oxoadenines **1**--**5** were more potent IFNα inducers than SM360320 and R848, except oxoadenines **2a** (aminoethyl), **3a,b** (azetidine), and **4d** (pyrrolidine) that were less potent IFNα inducers than R848. Oxoadenines with no carbon linker did not induce measurable TNFα in the dose range evaluated ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)), indicating that azetidinyl and pyrrolidinyl oxoadenines **3a**, **4a**, and **4d** are specific inducers of IFNα over TNFα in the dose range evaluated. We previously reported that the 0C-linked piperidine oxoadenine was unable to induce either IFNα or TNFα in hPBMC.^[@ref57]^ Although the 1C-linker derivatives **1a** and **3b** and the aminobutyl oxoadenine **2b** were the most potent hTLR8 agonists of this series (EC~50~ \< 200 μM) in the HEK293-hTLR8 NFκB reporter assay, longer carbon linkers led to lower MEC and higher TNFα peak levels ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)). This trend was previously reported in other piperidinylalkyl oxoadenine series with 5- or 6-carbon linker oxoadenines being more potent TNFα inducers.^[@ref43],[@ref57]^ This result is not unexpected since the longer linker derivatives were the most potent NFκB inducers in the HEK293-hTLR7 reporter assay. Thus, TNFα induction observed in hPBMCs for oxoadenines **1b,c** most likely originates from the hTLR7/NFκB pathway, while TNFα induced by oxoadenine **2b** most likely originates from both hTLR7/NFκB and hTLR8 pathways. Oxoadenines **1**--**4** were less inflammatory than R848, and only piperidinyl oxoadenines **1b,c** and aminobutyl oxoadenine **2b** were more inflammatory than SM360320. These trends were shared among the three donors tested, although donor-to-donor differences in terms of peak level and minimum effective dose were observed.

### Heterocycle Chirality {#sec2.2.2}

Both (*R*) and (*S*) isomers of 3-pyrrolidinylalkyl (**4a**,**d**, **4b**,**e**, **4c**,**f**) and 3-piperidinylalkyl (**5a**,**b**) oxoadenines were synthesized and evaluated to investigate the effect of the N-heterocycle chirality on biological activity. In the pyrrolidine series, the (*R*) isomers **4a--c** were 1.6- to 4-fold more potent in the HEK293-hTLR7 NFκB reporter assay than the corresponding (*S*) isomers **4d**--**f** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)). In the piperidinemethyl series, the (*S*) isomer **5b** was about 2.4-fold more potent than the corresponding (*R*) isomer **5a**. These results indicate that the chirality of the 9-substituent has no significant influence on hTLR7 activity. Comparing the 3-piperidinemethyl isomers **5a** and **5b** to the 4-piperidinemethyl **1a** also indicates that the position (3 versus 4) of the heterocyclic N atom has little influence on hTLR7 activity. While the ring chirality had little effect on hTLR8 activity (HEK293-hTLR8 NFκB reporter assay) in the pyrrolidine series (**4a**--**f**), the (*S*)-3-piperidinylmethyl derivative **5b** was more hTLR8 active than the corresponding (*R*) isomer **5a**. The position of the N atom in the piperidine ring (3 versus 4) had a larger influence on hTLR8 activity with the 4-piperidinemethyl oxoadenine **1a** being more hTLR8 potent than either 3-piperidinemethyl isomers **5a** and **5b**.

In the pyrrolidine series, the 0C-linker (*R*) isomer **4a** was more potent at inducing IFNα from human PBMCs (lower MEC and higher PL, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)) than the corresponding (*S*) isomer **4d**, but this potency increase for the (*R*) isomer vanished when increasing the linker length to 1C and 2C (**4b**/**4e** and **4c**/**4f**). In the piperidinemethyl series, both (*R*) and (S) isomers **5a** and **5b** displayed the same MEC and PL for IFNα induction, while the 4-piperidinemethyl **1a**, which had the same MEC as the 3-piperidinemethyl **5a** and **5b**, induced the highest IFNα peak level ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)). No significant difference in TNFα secretion was observed among the isomer pairs. In conclusion, the chirality of the N-heterocyclic substituent had a negligible effect on hTLR7/8 activity in the HEK293-hTLR7/8 NFκB reporter assay and on IFNα/TNFα induction from primary human PBMCs.

### Ring Size {#sec2.2.3}

We also examined the effect of the ring size (azetidine, pyrrolidine, and piperidine) on biological activity. In the ethyl linker series, there was a clear increase in hTLR7 potency (HEK293-hTLR7 NFκB reporter assay) with increasing ring size ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)). Replacing the primary amine group in **2a** with an azetidine ring (**3c**) increased hTLR7 potency by 42-fold. Increasing the ring size from azetidine (**3c**) to pyrrolidine (**4c**,**f**) further increased hTLR7 potency by 3-fold. This trend held true for both azetidine and pyrrolidine derivatives regardless of the linker length (*n* = 0--2) with the pyrrolidine derivatives **4a**,**d** and **4b**,**e** being 2- to 7-fold more potent than the corresponding azetidine derivatives **3a** and **3b** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)).

There was a correlation between IFNα induction and ring size. The MEC and PC for IFNα induction decreased with increasing ring size, while IFNα PL increased with increasing ring size, regardless of the carbon linker ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S4](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)). In contrast, the ring size had a negligible effect on TNFα induction from primary human PBMCs.

### Heterocycle Substitution {#sec2.2.4}

After investigating the effect of the linker length, ring chirality, and size on hTLR7/8 activity and cytokine induction, we selected the piperidine-substituted oxoadenine scaffold to further investigate the effects of substituting the piperidine ring with amino- and hydroxyl-alkyl groups. We are interested in introducing a functional group onto the oxoadenine scaffold that will retain or improve the desired hTLR7 activity while allowing subsequent conjugation to phospholipids or antigens to improve efficacy and safety when used as a vaccine adjuvant. The 4-piperidinemethyl oxoadenine **1a** was first substituted at the 1-position of the piperidine ring with a hydroxyethyl (**6a**), hydroxybutyl (**6b**), hydroxyhexyl (**6c**), or aminoethyl (**6d**) group. Introduction of a hydroxyalkyl group on **1a** had little effect on HEK293-hTLR7 activity with both hydroxyethyl- and hydroxybutyl-substituted oxoadenines **6a**,**b** being similarly potent than unsubstituted oxoadenine **1a** and hydroxyhexyl oxoadenine **6c** being 1.6-fold more potent than **1a** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S5](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)). Within the hydroxyalkyl series **6a**--**c**, there was a slight trend toward increased hTLR7 potency with increasing alkyl length. The aminoethyl oxoadenine **6d** was about 3-fold less potent than the unsubstituted oxoadenine **1a** and the hydroxyethyl oxoadenine **6a**, indicating that replacing the hydroxyl group in **6a** with an amine group slightly decreases TLR7 potency. Substituted oxoadenines **6a,b,d** were the most potent hTLR8 agonist of the series with EC~50~ \< 50 μM. Oxoadenine **6a**, the most potent hTLR8 agonist of the series (EC~50~ = 12.5 μM), was also the only TLR8-selective agonist of the series ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}).

The hydroxyhexyl derivative **6c** had the lowest MEC for IFNα induction from PBMCs, indicating that a longer hydroxyalkyl substituent increased IFNα potency ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S6](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)). While both hydroxyethyl and hydroxybutyl derivatives **6a**,**b** displayed similar MEC as unsubstituted oxoadenine **1a**, they induced lower IFNα PL. Interestingly, despite displaying the highest IFNα MEC, the aminoethyl derivative **6d** induced IFNα PL as high as PL induced by **1a**. Oxoadenines **6a**--**d** induced much higher IFNα peak levels than benchmarks R848 and SM360320. Both hydroxyl and aminoethyl oxoadenines **6a** and **6d** were the most potent TNFα inducers of the series, inducing about 2.5-fold higher TNFα PL than unsubstituted oxoadenine **1a**. TNFα induction decreased with increasing alkyl chain length, indicating a correlation between alkyl chain length and TNFα induction. Oxoadenines **6a**--**d** were weaker TNFα inducers than R848. In conclusion, the substitution of the piperidine ring had a minimal effect on hTLR7/NFκB activity while increasing hTLR8 activity in the HEK293 reporter assay. Substitution of the piperidine ring had also a pronounced effect on cytokine induction. The longer hydroxyhexyl group (**6c**) led to the most active IFNα inducer and lowest TNFα inducer of the series, while both amino- and hydroxy-ethyl groups (**6a** and **6d**) led to higher levels of TNFα.

We next investigated the introduction of an amine or hydroxyl group at the 4-position of the piperidine ring N-linked to the oxoadenine scaffold via an ethyl linker (**8a** and **8b**). **8a** and **8b** were 21- and 16-fold less active in the HEK293-hTLR7 cells than the 4-ethyl piperidine **1b** derivative ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S5](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)). Since we did not test the N-linked piperidineethyl analog of **1b**, we cannot conclude if the drop in hTLR7 potency observed for **8a** and **8b** is due to the introduction of the hydroxyl or amine group, the presence of an N-linked versus a C-linked piperidine ring, or a combination of both. The hydroxy-substituted oxoadenine **8b** was more active than the corresponding amino derivative **8a** in the HEK293-hTLR8 reporter assay and was one of the most active hTLR8 agonists of the series with an EC~50~ of 50.4 μM ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Both **8a** and **8b** were weak inducers of IFNα from primary hPBMCs when compared to **1b** with an MEC for IFNα 125-fold higher than **1b** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S6](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)). Although we did not test the N-linked analog of **1b**, the two homologous N-linked and C-linked piperidinebutyl oxoadenines have been previously described and their IFNα pEC~50~ reported as 8.2 and 9.2, respectively,^[@ref43]^ indicating a 10-fold decrease in IFNα potency when switching a C-linked to an N-linked piperidine. In light of this observation, it is tempting to speculate that the lower IFNα levels detected with **8a** and **8b** compared to those with **1b** were the result of introducing an amino or hydroxyl group in combination with linking the piperidine ring via the N atom. The amino derivative **8a** displayed a higher IFNα MEC than **1b** but induced similar IFNα PL as **1b**. Both hydroxyl and amine derivatives **8a** and **8b** were lower activators of TNFα (higher MEC) than **1b** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S6](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)).

### Nitrogen Number in N-Heterocycle {#sec2.2.5}

We finally investigated the replacement of the piperidine ring (**1b**,**c**) with a piperazine ring (**7a**,**b**). Both piperazineethyl (**7a**) and piperazinebutyl (**7b**) were 12-fold and 5-fold less active in the HEK293-hTLR7 reporter assay than the corresponding piperidine analogs **1b** and **1c**, respectively ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S5](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)). As previously noted in the piperidine series, increasing the linker length from an ethyl to a butyl in the piperazinealkyl series also increased hTLR7 potency by 3-fold. Both piperazine derivatives displayed low hTLR8 activity in the HEK293-hTLR8 reporter assay ([Figure S5](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)). While increasing the linker length in the piperidine series (**1a**--**c**) led to more potent IFNα induction from human PBMCs, the linker length in the piperazine series had no effect on IFNα induction with both ethyl and butyl derivatives **7a** and **7b** displaying near-identical IFNα MEC and PL ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S6](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)). Both **7a** and **7b** were less potent IFNα inducers than the ethyl piperidine **1b** but more active than R848 and SM360320. As expected from both HEK293-hTLR7 and hTLR8 assays, both piperazine derivatives also induced lower levels of TNFα than the piperidine derivatives ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S6](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf)). The lower activity of the piperazine derivatives compared to that of the corresponding piperidine derivatives might be explained by their lower basicity. Since TLR7 receptors are localized in endosomal compartments^[@ref30]^ and require endosomal acidification for ligand recognition and signaling,^[@ref60]^ less basic compounds might accumulate at lower concentrations in these acidic compartments leading to lower potencies.

Conclusions {#sec3}
===========

Twenty-four oxoadenines substituted at the N-9-position with various N-heterocycles were synthesized in two to four steps from a common advanced intermediate to investigate the effect of the linker length and N-heterocycle ring size, substitution and chirality on TLR7/8 specificity, potency, and cytokine (IFNα and TNFα) induction. Most oxoadenines **1**--**8** activated hTLR7 in the micromolar range and six oxoadenines (**2b**, **6a**--**d**, and **8b**) activated hTLR8 with EC~50~ \< 50 μM. Oxoadenine **6a** was also found to be TLR8-selective. The results show that hTLR7/8 activity correlated primarily to linker length and to a lesser extent to ring size, while ring chirality had little effect on TLR7/8 activity. This activity was confirmed when evaluating IFNα and TNFα induction from PBMC isolated from healthy adult human donors. Substitution of the heterocyclic ring with an aminoalkyl or hydroxyalkyl group, for future conjugation to phospholipids or antigens, was well tolerated with the retention of TLR7 activity and slight enhancement of TLR8 activity. The broad tolerability of a wide variety of substituents at the N-9-position of the oxoadenine scaffold has been previously reported.^[@ref43],[@ref61]^ Among the structural features evaluated in this study, combining a butyl linker with a piperidine ring led to the most potent IFNα and TNFα inducers, while directly attaching an azetidinyl or pyrrolidinyl ring to the oxoadenine scaffold led to selective IFNα release in the dose range evaluated. The N-heterocycle derivatives reported herein further advance the SAR of this important and clinically relevant TLR7/8 agonist scaffold. In addition, the synthesis and biological evaluation of phospholipid derivatives of certain oxoadenines presented in this study (manuscript in preparation) and advancement toward in vivo testing in models of vaccine adjuvant and immunotherapy will provide additional insight into the unique biological properties of the compounds reported herein.

Experimental Section {#sec4}
====================

Chemistry {#sec4.1}
---------

Solvents and reagents were purchased and used without further purification. Moisture- or air-sensitive reactions were conducted under nitrogen atmosphere in oven-dried (120 °C) glassware. Solvents were removed under reduced pressure using rotary evaporators. Thin-layer chromatography (TLC) was performed on precoated EMD Millipore TLC Silica Gel 60 F~254~ glass plates with visualization by UV light (254 nm) and by staining with an ethanolic acidic vanillin solution. Flash chromatography purifications were performed using Reveleris Standard Silica Flash Cartridges on a Büchi Reveleris X2 flash chromatography system. NMR (^1^H and ^13^C) spectra were recorded on a Varian 400-MR DD2 magnetic resonance system in the noted solvent using tetramethylsilane as an internal standard. Purity for all final compounds was confirmed to be greater than 95% by LC--MS using an ACE 3 C8 column (50 × 3.0 mm^2^, with a flow rate of 0.5 mL/min, a temperature of 40 °C, and a detection at 254 nm) with a 0--100% gradient of 0.5 M ammonium carbonate/water to 0.5 M ammonium carbonate/2-propanol in an Agilent 6220 accurate-mass TOF equipped with an Agilent 1100 HPLC. High-resolution mass spectra were obtained on the same instrument. Compounds were formulated at 3--5 mg/mL in 2% glycerol--10% dimethyl sulfoxide (DMSO) in water. Up to 50% DMSO was added for **6c** and **10a,b**. SM360320 was formulated in DMSO.

General Procedure for *N*-Alkylation of CAI **9** {#sec4.2}
-------------------------------------------------

Potassium carbonate (325 mesh, 3.0 equiv) was added to a solution of **9** in DMF (0.25 M). The reaction mixture was sonicated several seconds to obtain a fine suspension and stirred at 60 °C for 1 h. After cooling to 50 °C, the alkyl bromide or iodide (1.2 equiv) was added, and the reaction mixture was stirred overnight at 50 °C. After cooling to rt and aqueous workup (ethyl acetate or methyl *tert*-butyl ether/water), the resulting crude was purified by chromatography on silica gel (gradient 0--10% CH~3~OH in CHCl~3~). In some cases, the desired 9-alkylated product was isolated with up to 30% of the corresponding 7-alkylated regioisomer. These two isomers were easily separated after the subsequent acidic deprotection step.

General Procedure for Acidic Deprotection {#sec4.3}
-----------------------------------------

The purified alkylation product was dissolved in methanol (0.1 M) and reacted with 4 N HCl in dioxane (6.0 equiv) at rt for 1 h. The reaction mixture was concentrated and dried under vacuum, and the residue was purified by chromatography on silica gel (0--100% CHCl~3~/CH~3~OH/H~2~O 75/25/1.0 in CHCl~3~/CH~3~OH/H~2~O 85/15/0.5).

### 1,1-Dimethylethyl 2-\[(6-Amino-2-butoxy-8-methoxy-9*H*-purin-9-yl)\]-1-ethyl Carboxylate **10a** {#sec4.3.1}

The title compound was prepared according to the general *N*-alkylation procedure using commercially available 1,1-dimethylethyl (2-bromoethyl)carbamate. **10a** was isolated with approximately 30% of the corresponding 7-alkylated isomer as an off-white solid in an 86% yield. ^1^H NMR (CDCl~3~/CD~3~OD, 400 MHz), δ 5.37 (1H), 5.12 (s, 2H), 4.28 (t, *J* = 6.5 Hz, 2H), 4.12 (s, 3H), 4.08 (t, *J* = 5.4 Hz, 2H), 3.49 (m, 2H), 1.77 (p, *J* = 6.6 Hz, 2H), 1.51 (q, *J* = 7.6 Hz, 2H), 1.38 (s, 9H), 0.97 (t, *J* = 7.3 Hz, 3H). HRMS calculated for C~17~H~28~N~6~O~4~ \[M + H\]^+^ 381.2250; found 381.2233.

### 1,1-Dimethylethyl 4-\[(6-Amino-2-butoxy-8-methoxy-9*H*-purin-9-yl)\]-1-butyl Carboxylate **10b** {#sec4.3.2}

The title compound was prepared according to the general *N*-alkylation procedure using commercially available 1,1-dimethylethyl (4-bromobutyl)carbamate. **10b** was isolated with approximately 30% of the corresponding 7-alkylated isomer as an off-white solid in quantitative yield. ^1^H NMR (CDCl~3,~ 400 MHz), δ 5.08 (s, 2H), 4.56 (s, 1H), 4.27 (t, *J* = 6.6 Hz, 2H), 4.11 (s, 3H), 3.95 (t, *J* = 6.9 Hz, 2H), 3.15 (m, 2H), 1.76 (m, 4H), 1.36--1.53 (m, 13H), 0.96 (t, *J* = 7.3 Hz, 3H). HRMS calculated for C~19~H~32~N~6~O~4~ \[M + H\]^+^ 409.2563; found 409.2537.

### 1,1-Dimethylethyl 3-(6-Amino-2-butoxy-8-methoxy-9*H*-purin-9-yl)-1-azetidine Carboxylate **11a** {#sec4.3.3}

The title compound was prepared as an off-white solid in a 62% yield, according to the general *N*-alkylation procedure using commercially available 1-*tert*-butoxycarbonyl-3-iodoazetidine. ^1^H NMR (CDCl~3~, 400 MHz), δ 5.37 (s, 2H), 5.20 (m, 1H), 4.59 (t, *J* = 7.2 Hz, 2H), 4.27 (m, 4H), 4.14 (s, 3H), 1.75 (m, 2H), 1.42--1.54 (m, 11H), 0.96 (t, *J* = 7.3 Hz, 3H). HRMS calculated for C~18~H~28~N~6~O~4~ \[M + H\]^+^ 393.2250; found 393.2261.

### 1,1-Dimethylethyl 3-\[(6-Amino-2-butoxy-8-methoxy-9*H*-purin-9-yl)methyl\]-1-azetidine Carboxylate **11b** {#sec4.3.4}

The title compound was prepared as a light yellow solid in a 66% yield, according to the general *N*-alkylation procedure using commercially available 1-*tert*-butoxycarbonyl-3-(bromomethyl)azetidine. ^1^H NMR (CDCl~3~, 400 MHz), δ 5.14 (s, 2H), 4.27 (t, *J* = 6.5 Hz, 2H), 4.10--4.17 (m, 5H), 3.97 (t, *J* = 8.5 Hz, 2H), 3.77 (t, *J* = 6.9 Hz, 2H), 3.04 (m, 1H) 1.69--1.80 (m, 2H), 1.53 (m, 2H), 1.48 (s, 9H), 0.97 (t, *J* = 7.3 Hz, 3H). HRMS calculated for C~19~H~30~N~6~O~4~ \[M + H\]^+^ 407.2407; found 407.2427.

### 1,1-Dimethylethyl 3-\[(6-Amino-2-butoxy-8-methoxy-9*H*-purin-9-yl)ethyl\]-1-azetidine Carboxylate **11c** {#sec4.3.5}

The title compound was prepared as a light yellow solid in a 74% yield, according to the general *N*-alkylation procedure using commercially available 1-*tert*-butoxycarbonyl-3-(bromoethyl)azetidine. ^1^H NMR (CDCl~3~, 400 MHz), δ, 5.12 (s, 2H), 4.27 (t, *J* = 6.7 Hz, 2H), 4.11 (s, 3H), 3.91--3.98 (m, 4H), 3.53 (m, 2H), 2.45 (m, 1H), 2.05 (q, *J* = 7.0 Hz, 2H), 1.77 (m, 2H), 1.35--1.55 (m, 11H), 0.97 (t, *J* = 7.3 Hz, 3H). HRMS calculated for C~20~H~32~N~6~O~4~ \[M + H\]^+^ 421.2563; found 421.2587.

### 1,1-Dimethylethyl (3*R*)-\[(6-Amino-2-butoxy-8-methoxy-9*H*-purin-9-yl)\]-1-pyrrolidine Carboxylate **12a** {#sec4.3.6}

The title compound was prepared according to the general *N*-alkylation procedure using commercially available (*S*)-3-bromo-pyrrolidine-1-carboxylic acid *tert*-butyl ester. **12a** was isolated with approximately 30% of the corresponding 7-alkylated isomer as a light yellow solid in a 54% yield. ^1^H NMR (CDCl~3~, 400 MHz), δ 5.11 (bs, 2H), 5.01 (m, 1H), 4.26 (t, *J* = 6.6 Hz, 2H), 4.12 (s, 3H), 3.74 (m, 2H), 3.45 (m, 2H), 2.68 (m, 1H), 2.21 (m, 1H), 1.77 (m, 2H), 1.47 (s, 11H), 0.96 (t, *J* = 7.4 Hz, 3H). HRMS calculated for C~19~H~30~N~6~O~4~ \[M + H\]^+^ 407.2407; found 407.2431.

### 1,1-Dimethylethyl (3*S*)-\[(6-Amino-2-butoxy-8-methoxy-9*H*-purin-9-yl)methyl\]-1-pyrrolidine Carboxylate **12b** {#sec4.3.7}

The title compound was prepared as a light yellow solid in a 93% yield, according to the general *N*-alkylation procedure using commercially available (*R*)-3-bromomethyl-pyrrolidine-1-carboxylic acid *tert*-butyl ester. **12b** was isolated with approximately 30% of the corresponding 7-alkylated isomer. ^1^H NMR (CDCl~3~, 400 MHz), δ 5.13 (s, 2H), 4.27 (t, *J* = 6.6 Hz, 2H), 4.11 (s, 3H), 3.89--3.98 (m, 2H), 3.47 (m, 2H), 3.30 (m, 1H), 3.13 (m, 1H), 2.75 (m, 1H), 1.89 (m, 1H), 1.76 (m, 2H), 1.67 (m, 1H), 1.40--1.54 (m, 11H), 0.96 (t, *J* = 7.3 Hz, 3H). HRMS calculated for C~20~H~32~N~6~O~4~ \[M + H\]^+^ 421.2563; found 421.2590.

### 1,1-Dimethylethyl (3*S*)-\[(6-Amino-2-butoxy-8-methoxy-9*H*-purin-9-yl)ethyl\]-1-pyrrolidine Carboxylate **12c** {#sec4.3.8}

Triphenylphosphine (1.2 equiv) was slowly added to a cold solution (0 °C) of (*R*)-3-hydroxyethyl-pyrrolidine-1-carboxylic acid *tert*-butyl ester and carbon tetrabromide (1.6 equiv) in methylene chloride (0.45 M), and the resulting solution was stirred at rt for 45 min. The concentrated reaction mixture was directly purified by chromatography on silica gel (0--50% ethyl acetate in heptane) to give (*R*)-3-bromoethyl-pyrrolidine-1-carboxylic acid *tert*-butyl ester as a colorless oil in an 83% yield. ^1^H NMR (CDCl~3~, 400 MHz), δ 3.35--3.65 (m, 5H), 3.28 (m, 1H), 2.90 (m, 1H), 2.35 (m, 1H), 1.87--2.10 (m, 3H), 1.46 (m, 9H). The title compound was prepared as a viscous light yellow oil in an 87% yield, according to the general *N*-alkylation procedure using (*R*)-3-bromoethyl-pyrrolidine-1-carboxylic acid *tert*-butyl ester. ^1^H NMR (CDCl~3~, 400 MHz), δ, 5.10 (s, 2H), 4.27 (t, *J* = 6.6 Hz, 2H), 4.12 (s, 3H), 3.96 (t, *J* = 5.8 Hz, 2H), 3.37--3.54 (m, 2H), 3.22 (m, 1H), 2.85 (m, 1H), 2.04 (m, 2H), 1.85 (m, 2H), 1.77 (m, 2H), 1.70 (m, 1H), 1.41--1.54 (m, 11H), 0.96 (t, *J* = 7.3 Hz, 3H).

### 1,1-Dimethylethyl (3*S*)-\[(6-Amino-2-butoxy-8-methoxy-9H-purin-9-yl)\]-1-pyrrolidine Carboxylate **12d** {#sec4.3.9}

The title compound was prepared as a light yellow solid in a 52% yield, according to the general *N*-alkylation procedure using commercially available (*R*)-3-bromo-pyrrolidine-1-carboxylic acid *tert*-butyl ester. ^1^H NMR (CDCl~3~, 400 MHz), δ 5.14 (bs, 2H), 5.01 (m, 1H), 4.26 (t, *J* = 6.6 Hz, 2H), 4.12 (s, 3H), 3.75 (m, 2H), 3.45 (m, 2H), 2.68 (m, 1H), 2.20 (m, 1H), 1.75 (m, 2H), 1.47 (s, 11H), 0.96 (t, *J* = 7.4 Hz, 3H). HRMS calculated for C~19~H~30~N~6~O~4~ \[M + H\]^+^ 407.2407; found 407.2402.

### 1,1-Dimethylethyl (3*R*)-\[(6-Amino-2-butoxy-8-metloxy-9H-purin-9-yl)methyl\]-1-pyrrolidine Carboxylate **12e** {#sec4.3.10}

The title compound was prepared according to the general *N*-alkylation procedure using commercially available (*S*)-3-bromomethyl-pyrrolidine-1-carboxylic acid *tert*-butyl ester and isolated with about 10% of the corresponding 7-regioisomer as a light yellow solid in an 80% yield. ^1^H NMR (CDCl~3~, 400 MHz), δ 5.11 (s, 2H), 4.27 (t, *J* = 6.6 Hz, 2H), 4.11 (s, 3H), 3.92 (m, 2H), 3.47 (m, 2H), 3.30 (m, 1H), 3.13 (m, 1H), 2.75 (m, 1H), 1.90 (m, 1H), 1.76 (m, 2H), 1.67 (m, 1H), 1.42--1.54 (m, 11H), 0.96 (t, *J* = 7.3 Hz, 3H). HRMS calculated for C~20~H~32~N~6~O~4~ \[M + H\]^+^ 421.2563; found 421.2554.

### 1,1-Dimethylethyl (3*R*)-\[(6-Amino-2-butoxy-8-methoxy-9H-purin-9-yl)ethyl\]-1-pyrrolidine Carboxylate **12f** {#sec4.3.11}

Triphenylphosphine (1.2 equiv) was slowly added to a cold solution (0 °C) of (*S*)-3-hydroxyethyl-pyrrolidine-1-carboxylic acid *tert*-butyl ester and carbon tetrabromide (1.6 equiv) in methylene chloride (0.45 M), and the resulting solution was stirred at rt for 45 min. The concentrated reaction mixture was directly purified by chromatography on silica gel (0--50% ethyl acetate in heptane) to give (*S*)-3-bromoethyl-pyrrolidine-1-carboxylic acid *tert*-butyl ester as a colorless oil in a 79% yield. ^1^H NMR (CDCl~3~, 400 MHz), δ 3.35--3.65 (m, 5H), 3.28 (m, 1H), 2.90 (m, 1H), 2.35 (m, 1H), 1.87--2.10 (m, 3H), 1.46 (m, 9H). The title compound was prepared as a viscous yellowish oil in a 90% yield, according to the general *N*-alkylation procedure using (*S*)-3-bromoethyl-pyrrolidine-1-carboxylic acid *tert*-butyl ester. ^1^H NMR (CDCl~3~, 400 MHz), δ 5.17 (s, 2H), 4.27 (t, *J* = 6.6 Hz, 2H), 4.12 (s, 3H), 3.96 (t, *J* = 5.9 Hz, 2H), 3.60--3.74 (m, 1H), 3.40 (m, 1H), 3.23 (m, 1H), 2.84--2.99 (m, 1H), 2.04 (m, 2H), 1.85 (m, 2H), 1.71--1.81 (m, 3H), 1.43--1.57 (m, 11H), 0.96 (t, *J* = 7.4 Hz, 3H).

### 6-Amino-2-butoxy-9-{1-\[1-(dimethyl-*tert*-butylsilyloxy)ethyl-4-piperidinyl\]methyl}-8-methoxy-9*H*-purin **14a** {#sec4.3.12}

The title compound was prepared as a white solid in a 79% yield by alkylation of **1a** with commercially available (2-bromoethoxy)-*tert*-butyldimethylsilane according to the general *N*-alkylation procedure and a 3 h reaction time. ^1^H NMR (CDCl~3~/CD~3~OD, 400 MHz), δ 4.26 (t, *J* = 6.6 Hz, 2H), 3.72--3.80 (m, 4H), 2.97 (d, *J* = 11.1 Hz, 2H), 2.54 (t, *J* = 6.2 Hz, 2H), 2.11 (t, *J* = 11.0 Hz, 2H), 1.93 (s, 1H), 1.75 (m, 2H), 1.67 (m, 2H), 1.36--1.53 (m, 4H), 0.98 (t, *J* = 7.4 Hz, 3H), 0.89 (s, 9H), 0.06 (s, 6H). HRMS calculated for C~23~H~42~N~6~O~3~Si \[M + H\]^+^ 479.3166; found 479.3170.

### 6-Amino-2-butoxy-9-{1-\[1-(dimethyl-*tert*-butylsilyloxy)butyl-4-piperidinyl\]methyl}-8-methoxy-9*H*-purin **14b** {#sec4.3.13}

The title compound was prepared as a white solid in an 83% yield by alkylation of **1a** with commercially available (4-bromobutyloxy)-*tert*-butyldimethylsilane according to the general *N*-alkylation procedure and a 4 h reaction time. ^1^H NMR (CD~3~OD, 400 MHz), δ 4.28 (t, *J* = 6.5 Hz, 2H), 3.73 (d, *J* = 7.0 Hz, 2H), 3.65 (t, *J* = 6.1 Hz, 2H), 3.04 (d, *J* = 10.7 Hz, 2H), 2.46 (m, 2H), 2.11 (m, 2H), 1.97 (m, 1H), 1.70--1.76 (m, 4H), 1.58--1.64 (m, 2H), 1.39--1.54 (m, 6H), 0.98 (t, *J* = 7.4 Hz, 3H), 0.90 (s, 9H), 0.05 (s, 6H). HRMS calculated for C~25~H~46~N~6~O~3~Si \[M + H\]^+^ 507.3479; found 507.3465.

### 6-Amino-2-butoxy-9-{1-\[1-(dimethyl-*tert*-butylsilyloxy)hexyl-4-piperidinyl\]methyl}-8-methoxy-9*H*-purin **14c** {#sec4.3.14}

The title compound was prepared as a white solid in an 82% yield by alkylation of **1a** with commercially available (6-bromohexyloxy)-*tert*-butyldimethylsilane according to the general *N*-alkylation procedure and a 2 h reaction time. ^1^H NMR (CD~3~OD, 400 MHz), δ 4.28 (t, *J* = 6.6 Hz, 2H), 3.74 (d, *J* = 6.9 Hz, 2H), 3.63 (t, *J* = 6.3 Hz, 2H), 3.11 (d, *J* = 11.1 Hz, 2H), 2.53 (m, 2H), 2.23 (m, 2H), 2.00 (m, 1H), 1.71--1.76 (m, 4H), 1.29--1.61 (m, 12H), 0.98 (t, *J* = 7.4 Hz, 3H), 0.90 (s, 9H), 0.05 (s, 6H). HRMS calculated for C~27~H~50~N~6~O~3~Si \[M + H\]^+^ 535.3792; found 535.3784.

### 6-Amino-2-butoxy-9-{1-\[1-\[(*tert*-butyloxycabonyl)amino\]ethyl-4-piperidinyl\]methyl}-8-methoxy-9*H*-purin **14d** {#sec4.3.15}

The title compound was prepared as a white solid in a 67% yield by alkylation of **1a** with commercially available 2-\[(*tert*-butoxycarbonyl)amino\]ethyl bromide according to the general *N*-alkylation procedure and a 7 h reaction time. ^1^H NMR (CDCl~3~/CD~3~OD, 400 MHz), δ 4.25 (t, *J* = 6.5 Hz, 2H), 3.73 (d, *J* = 6.3 Hz 2H), 3.38 (m, 2H), 3.20 (m, 2H), 2.88 (m, 2H), 2.44 (m, 2H), 1.94 (m, 3H), 1.75 (m, 2H), 1.66 (m, 2H), 1.34--1.53 (m, 13H), 0.97 (t, *J* = 7.2 Hz, 3H). HRMS calculated for C~22~H~37~N~7~O~4~ \[M + H\]^+^ 464.2985; found 454.2986.

### 6-Amino-2-butoxy-9-(4-chlorobutyl)-8-methoxy-9*H*-purin **15** {#sec4.3.16}

The title compound was prepared as a pale yellow oil in a 96% yield by alkylation of **9** with 1-bromo-4-chlorobutane (1.1 equiv) according to the general *N*-alkylation procedure and stirring at rt for 66 h after bromide addition. ^1^H NMR (CDCl~3~, 400 MHz), δ 5.80 (s, 2H), 4.27 (t, *J* = 6.7 Hz, 2H), 4.11 (s, 3H), 3.97 (t, *J* = 6.7 Hz, 2H), 3.58 (t, *J* = 6.4 Hz, 2H), 1.93 (m, 2H), 1.76 (m, 4H), 1.48 (m, 2H), 0.96 (t, *J* = 7.4 Hz, 3H). HRMS calculated for C~14~H~22~ClN~5~O~2~ \[M + H\]^+^ 328.1540; found 328.1537.

### 1,1-Dimethylethyl \[(6-Amino-2-butoxy-8-methoxy-9*H*-purin-9-yl)ethyl\]-1-piperazine Carboxylate **16a** {#sec4.3.17}

The title compound was prepared as a viscous yellowish oil in a 74% yield, according to the general *N*-alkylation procedure using *tert*-butyl 4-(2-bromoethyl)piperazine-1-carboxylate. ^1^H NMR (CDCl~3~, 400 MHz), δ 5.66 (s, 2H), 4.25 (t, *J* = 6.6 Hz, 2H), 4.10 (s, 3H), 4.05 (t, *J* = 6.3 Hz, 2H), 3.35 (m, 4H), 2.71 (t, *J* = 6.3 Hz, 2H), 2.46 (m, 4H), 1.76 (m, 2H), 1.42--1.53 (m, 11H), 0.96 (t, *J* = 7.3 Hz, 3H). HRMS calculated for C~21~H~35~N~7~O~4~ \[M + H\]^+^ 450.2829; found 450.2825.

### 1,1-Dimethylethyl \[(6-Amino-2-butoxy-8-methoxy-9*H*-purin-9-yl)butyl\]-1-piperazine Carboxylate **16b** {#sec4.3.18}

**15** was reacted with DIPEA (2.0 equiv) and *tert*-butyl piperazine-1-carboxylate (1.2 equiv) in DMF (0.1 M) for 5 days at 60 °C. After aqueous workup (water/ethyl acetate), the crude was purified by chromatography on silica gel (0--1.5% CH~3~OH in CHCl~3~), and **16b** was isolated as a yellow viscous oil in a 48% yield. ^1^H NMR (CDCl~3~, 400 MHz), δ 5.09 (s, 2H), 4.27 (t, *J* = 6.6 Hz, 2H), 4.11 (s, 3H), 3.94 (t, *J* = 7.0 Hz, 2H), 3.37--3.47 (m, 4H), 2.34 (m, 6H), 1.76 (m, 4H), 1.62 (m, 2H), 1.43--1.52 (m, 11H), 0.96 (t, *J* = 7.4 Hz, 3H). HRMS calculated for C~23~H~39~N~7~O~4~ \[M + H\]^+^ 478.3142; found 478.3150.

### 6-Amino-2-butoxy-9-(2-bromoethyl)-8-methoxy-9*H*-purin **17** {#sec4.3.19}

The title compound was prepared as a pale yellow solid in a 54% yield by alkylation of **9** with 1,2-dibromoethane (1.0 equiv) according to the general *N*-alkylation procedure. ^1^H NMR (CDCl~3~, 400 MHz), δ 5.24 (s, 2H), 4.25--4.34 (m, 4H), 4.13 (s, 3H), 3.66 (t, *J* = 6.9 Hz, 2H), 1.76 (m, 2H), 1.50 (m, 2H), 0.97 (t, *J* = 7.4 Hz, 3H). HRMS calculated for C~12~H~18~BrN~5~O~2~ \[M + H\]^+^ 344.0722; found 344.0725.

### 6-Amino-2-butoxy-9-{2-\[4-(*tert*-butyloxycarbonyl)amino-1-piperidinyl\]ethyl}-8-methoxy-9*H*-purin **18a** {#sec4.3.20}

The title compound was prepared as a white solid in a 76% yield by alkylation of *tert*-butyl 4-amino-1-piperidinecarboxylate (1.1 equiv) with **17** according to the general *N*-alkylation procedure. ^1^H NMR (CDCl~3~, 400 MHz), δ 5.12 (s, 2H), 4.40 (m, 1H), 4.26 (t, *J* = 6.6 Hz, 2H), 4.10 (s, 3H), 4.03 (t, *J* = 6.6 Hz, 2H), 3.43 (m, 1H), 2.86 (m, 2H), 2.67 (t, *J* = 6.7 Hz, 2H), 2.14 (m, 2H), 1.87 (m, 2H), 1.73--1.80 (m, 4H), 1.41--1.54 (m, 11H), 0.96 (t, *J* = 7.4 Hz, 3H). HRMS calculated for C~22~H~37~N~7~O~4~ \[M + H\]^+^ 464.2985; found 464.3005.

### 6-Amino-2-butoxy-9-\[2-(4-hydroxy-1-piperidinyl)ethyl\]-8-methoxy-9*H*-purin **18b** {#sec4.3.21}

The title compound was prepared as a white solid in an 81% yield by alkylation of 4-hydroxypiperidine (1.1 equiv) with **17** according to the general *N*-alkylation procedure and 3 days reaction. ^1^H NMR (CDCl~3~/CD~3~OD, 400 MHz), δ 4.28 (t, *J* = 6.6 Hz, 2H), 4.13 (s, 3H), 4.09 (t, *J* = 6.9 Hz, 2H), 3.64 (m, 1H), 2.91 (m, 2H), 2.74 (t, *J* = 6.9 Hz, 2H), 2.28 (t, *J* = 9.7 Hz, 2H), 1.86 (m, 2H), 1.76 (m, 2H), 1.45--1.56 (m, 4H), 0.98 (t, *J* = 7.4 Hz, 3H). HRMS calculated for C~17~H~28~N~6~O~3~ \[M + H\]^+^ 365.2301; found 365.2319.

### 6-Amino-2-butoxy-9-(2-aminoethyl)-7,9-dihydro-8*H*-purin-8-one Hydrochloride **2a** {#sec4.3.22}

The title compound was prepared as an off-white solid in a 69% yield by acidic deprotection of **10a**, according to the general acidic deprotection procedure. ^1^H NMR (CDCl~3~/CD~3~OD, 400 MHz), δ 4.25 (t, *J* = 6.6 Hz, 2H), 3.97 (t, *J* = 6.0 Hz, 2H), 3.09 (t, *J* = 6.0 Hz, 2H), 1.74 (m, 2H), 1.47 (m, 2H), 0.97 (t, *J* = 7.3 Hz, 3H). ^13^C (CDCl~3~/CD~3~OD, 100 MHz) δ, 161.4, 154.6, 150.2, 149.1, 99.5, 67.8, 41.5, 40.3, 31.6, 19.7, 14.2. HRMS calculated for C~11~H~18~N~6~O~2~ \[M + H\]^+^ 267.1569; found 267.1562.

### 6-Amino-2-butoxy-9-(2-aminobutyl)-7,9-dihydro-8*H*-purin-8-one Hydrochloride **2b** {#sec4.3.23}

The title compound was prepared as an off-white solid in a 69% yield by acidic deprotection of **10b** according to the general acidic deprotection procedure. ^1^H NMR (CDCl~3~/CD~3~OD, 400 MHz), δ 4.27 (t, *J* = 6.0 Hz, 2H), 3.87 (t, *J* = 6.0 Hz, 2H), 2.99 (t, *J* = 6.8 Hz, 2H), 1.84 (m, 2H), 1.74 (m, 4H), 1.49 (q, *J* = 7.1 Hz, 2H), 0.98 (t, *J* = 7.0 Hz, 3H). ^13^C (CDCl~3~/CD~3~OD, 100 MHz) δ 160.3, 153.1, 149.0, 147.8, 98.2, 66.5, 38.5, 38.3, 30.5, 24.7, 23.9, 18.6, 13.0. HRMS calculated for C~13~H~22~N~6~O~2~ \[M + H\]^+^ 295.1882; found 295.1878.

### 6-Amino-2-butoxy-9-(3-azetidinyl)-7,9-dihydro-8*H*-purin-8-one Hydrochloride **3a** {#sec4.3.24}

The title compound was prepared as a white solid in an 84% yield by acidic deprotection of **11a**, according to the general acidic deprotection procedure. ^1^H NMR (CD~3~OD, 400 MHz), δ, 5.36 (m, 1H), 4.82 (t, *J* = 9.1 Hz, 2H), 4.32 (m, 4H), 1.74 (m, 2H), 1.49 (m, 2H), 0.98 (t, *J* = 7.3 Hz, 3H). ^13^C (CD~3~OD, 100 MHz) δ, 162.0, 154.1, 150.3, 150.2, 99.9, 68.2, 52.1, 44.4, 32.3, 20.3, 14.2. HRMS calculated for C~12~H~18~N~6~O~2~ \[M + H\]^+^ 279.1569; found 279.1564.

### 6-Amino-2-butoxy-9-(3-azetidinemethyl)-7,9-dihydro-8*H*-purin-8-one Hydrochloride **3b** {#sec4.3.25}

The title compound was prepared as a white solid in a 68% yield by acidic deprotection of **11b**, according to the general acidic deprotection procedure. ^1^H NMR (CD~3~OD, 400 MHz), δ 4.26 (t, *J* = 6.3 Hz, 2H), 4.03--4.17 (m, 6H), 3.37 (m, 1H), 1.72 (m, 2H), 1.49 (m, 2H), 0.98 (t, *J* = 7.3 Hz, 3H). ^13^C (CD~3~OD/CDCl~3~, 100 MHz) δ, 162.0, 155.0, 150.5, 149.8, 99.8, 68.1, 50.4, 42.2, 33.0, 31.9, 20.0, 14.2. HRMS calculated for C~13~H~20~N~6~O~2~ \[M + H\]^+^ 293.1726; found 293.1730.

### 6-Amino-2-butoxy-9-(3-azetidineethyl)-7,9-dihydro-8*H*-purin-8-one Hydrochloride **3c** {#sec4.3.26}

The title compound was prepared as a white solid in an 83% yield by acidic deprotection of **11c**, according to the general acidic deprotection procedure. ^1^H NMR (CD~3~OD, 400 MHz), δ 4.28 (t, *J* = 6.5 Hz, 2H,), 4.08 (m, 2H), 3.81 (m, 4H), 2.94 (m, 1H), 2.09 (m, 2H), 1.74 (m, 2H), 1.50 (m, 2H), 0.99 (t, *J* = 7.4 Hz, 3H).^13^C (CD~3~OD/CDCl~3~, 100 MHz) δ, 162.1, 154.8, 150.7, 149.8, 99.7, 68.0, 52.5, 38.1, 33.0, 32.2, 31.2, 20.2, 14.2. HRMS calculated for C~14~H~22~N~6~O~2~ \[M + H\]^+^ 307.1883; found 307.1880.

### 6-Amino-2-butoxy-9-\[(3*R*)-pyrrolidinyl\]-7,9-dihydro-8*H*-purin-8-one Hydrochloride **4a** {#sec4.3.27}

The title compound was prepared as a white solid in a 50% yield by acidic deprotection of **12a**, according to the general acidic deprotection procedure. ^1^H NMR (CD~3~OD/D~2~O, 400 MHz), δ 5.17 (m, 1H), 4.28 (t, *J* = 6.5 Hz, 2H), 3.65--3.74 (m, 2H), 3.48--3.56 (m, 1H), 3.27--3.38 (m, 1H), 2.49--2.58 (m, 1H), 2.28--2.37 (m, 1H), 1.75 (m, 2H), 1.49 (m, 2H), 0.98 (t, *J* = 7.4 Hz, 3H).^13^C (CD~3~OD/CDCl~3~, 100 MHz), δ 161.8, 154.3, 150.0, 149.9, 99.89, 68.1, 52.4, 50.8, 47.5, 32.1, 31.5, 20.2, 14.1. HRMS calculated for C~13~H~20~N~6~O~2~ \[M + H\]^+^ 293.1726; found 293.1717.

### 6-Amino-2-butoxy-9-\[(3*R*)-pyrrolidinylmethyl\]-7,9-dihydro-8*H*-purin-8-one Hydrochloride **4b** {#sec4.3.28}

The title compound was prepared as a white solid in an 86% yield by acidic deprotection of **12b**, according to the general acidic deprotection procedure. ^1^H NMR (CD~3~OD/D~2~O, 400 MHz), δ 4.23 (t, *J* = 6.4 Hz, 2H), 3.90 (m, 2H), 3.40 (m, 2H), 3.28 (m, 1H), 3.11 (m, 1H), 2.86 (m, 1H), 2.15 (m, 1H), 1.84 (m, 1H), 1.69 (m, 2H), 1.44 (m, 2H), 0.93 (t, J = 7.3 Hz, 3H).^13^C (CD~3~OD, 100 MHz), δ 162.0, 155.1, 150.5, 149.9, 99.7, 68.2, 46.1, 42.2, 39.0, 31.9, 28.9, 20.0, 14.1. HRMS calculated for C~14~H~22~N~6~O~2~ \[M + H\]^+^ 307.1882; found 307.1872.

### 6-Amino-2-butoxy-9-\[(3*R*)-pyrrolidinylethyl\]-7,9-dihydro-8*H*-purin-8-one Hydrochloride **4c** {#sec4.3.29}

The title compound was prepared as a white solid in an 86% yield by acidic deprotection of **12c**, according to the general acidic deprotection procedure. ^1^H NMR (CD~3~OD, 400 MHz), δ 4.27 (t, *J* = 6.5 Hz, 2H), 3.87 (t, *J* = 6.8 Hz, 2H), 3.49 (m, 1H), 3.36 (m, 1H), 3.20 (m, 1H), 2.88 (m, 1H), 2.28 (m, 2H), 1.91 (m, 2H), 1.62--1.77 (m, 3H), 1.49 (m, 2H), 0.99 (t, *J* = 7.4 Hz, 3H).^13^C (CD~3~OD/CDCl~3~, 100 MHz), δ 162.2, 155.0, 150.8, 149.9, 99.8, 68.0, 51.1, 46.3, 39.5, 36.9, 32.3, 32.2, 31.2, 20.3, 14.2. HRMS calculated for C~15~H~24~N~6~O~2~ \[M + H\]^+^ 321.2040, found 321.2025.

### 6-Amino-2-butoxy-9-\[(3*S*)-pyrrolidinyl\]-7,9-dihydro-8*H*-purin-8-one Hydrochloride **4d** {#sec4.3.30}

The title compound was prepared as a white solid in a 50% yield by acidic deprotection of **12d**, according to the general acidic deprotection procedure. ^1^H NMR (CD~3~OD/D~2~O, 400 MHz), δ 5.15 (m, 1H), 4.24 (m, 2H), 3.68 (m, 2H), 3.53 (m, 1H), 3.30 (m, 1H), 2.51 (m, 1H), 2.29 (m, 1H), 1.70 (m, 2H), 1.44 (m, 2H), 0.94 (m, 3H).^13^C (CD~3~OD/D~2~O, 100 MHz), δ 156.9, 153.7, 150.3, 144.5, 99.7, 71.3, 68.1, 51.8, 46.9, 31.6, 30.4, 20.0, 14.0. HRMS calculated for C~13~H~20~N~6~O~2~ \[M + H\]^+^ 293.1726; found 293.1717.

### 6-Amino-2-butoxy-9-\[(3*S*)-pyrrolidinylmethyl\]-7,9-dihydro-8*H*-purin-8-one Hydrochloride **4e** {#sec4.3.31}

The title compound was prepared as a white solid in an 82% yield by acidic deprotection of **12e**, according to the general acidic deprotection procedure. ^1^H NMR (CD~3~OD/D~2~O, 400 MHz), δ 4.21 (t, *J* = 6.4 Hz, 2H), 3.88 (m, 2H), 3.41 (m, 2H), 3.27 (m, 1H), 3.10 (m, 1H), 2.85 (m, 1H), 2.14 (m, 1H), 1.83 (m, 1H), 1.67 (m, 2H), 1.40 (m, 2H), 0.91 (t, *J* = 7.3 Hz, 3H).^13^C (CD~3~OD/D~2~O, 100 MHz), δ 161.9, 155.1, 150.4, 149.8, 99.7, 68.3, 46.1, 42.1, 38.8, 31.7, 28.8, 19.8, 14.1. HRMS calculated for C~14~H~22~N~6~O~2~ \[M + H\]^+^ 307.1882; found 307.1876.

### 6-Amino-2-butoxy-9-\[(3*S*)-pyrrolidinylethyl\]-7,9-dihydro-8*H*-purin-8-one Hydrochloride **4f** {#sec4.3.32}

The title compound was prepared as a white solid in a 59% yield by acidic deprotection of **12f**, according to the general acidic deprotection procedure. ^1^H NMR (CD~3~OD, 400 MHz), δ 4.28 (t, *J* = 6.5 Hz, 2H), 3.89 (t, *J* = 6.9 Hz, 2H), 3.49 (m, 1H), 3.34--3.40 (m, 1H), 3.17--3.24 (m, 1H), 2.89 (m, 1H), 2.28 (m, 2H), 1.91 (m, 2H), 1.65--1.77 (m, 3H), 1.49 (m, 2H), 0.97 (t, *J* = 7.4 Hz, 3H).^13^C (CD~3~OD/CDCl~3~, 100 MHz), δ 162.2, 155.0, 150.8, 149.9, 99.8, 68.0, 51.1, 46.3, 39.5, 36.9, 32.3, 31.2, 20.3, 14.2. HRMS calculated for C~15~H~24~N~6~O~2~ \[M + H\]^+^ 321.2040, found 321.2031.

### 6-Amino-2-butoxy-9-\[(1-hydroxyethyl-4-piperidinyl)methyl\]-7, 9-dihydro-8*H*-purin-8-one Hydrochloride **6a** {#sec4.3.33}

The title compound was prepared as a white solid in a quantitative yield by acidic deprotection of **14a**, according to the general acidic deprotection procedure. ^1^H NMR (CD~3~OD, 400 MHz), δ 4.50 (t, *J* = 6.4 Hz, 2H), 3.82--3.96 (m, 4H), 3.65 (m, 2H), 3.22 (m, 2H), 3.00 (m, 2H), 2.21 (m, 1H), 1.99 (m, 2H), 1.81 (m, 2H), 1.67 (m, 2H), 1.53 (m, 2H), 1.00 (t, *J* = 7.3 Hz, 3H).^13^C (CD~3~OD, 100 MHz), δ 156.6, 154.4, 151.3, 143.8, 99.4, 71.2, 60.0, 56.4, 53.7, 45.7, 34.6, 31.6, 28.2, 20.1, 14.1. HRMS calculated for C~17~H~28~N~6~O~3~ \[M + H\]^+^ 365.2303; found 365.2297.

### 6-Amino-2-butoxy-9-\[(1-hydroxybutyl-4-piperidinyl) methyl\]-7,9-dihydro-8*H*-purin-8-one Hydrochloride **6b** {#sec4.3.34}

The title compound was prepared as a white solid in an 89% yield by acidic deprotection of **14b**, according to the general acidic deprotection procedure. ^1^H NMR (CD~3~OD, 400 MHz), δ 4.26 (t, *J* = 6.5 Hz, 2H), 3.77 (d, *J* = 6.5 Hz, 2H), 3.60 (t, *J* = 6.0 Hz, 2H), 3.55 (m, 2H), 3.10 (t, *J* = 7.5 Hz, 2H), 2.94 (m, 2H), 2.20 (m, 1H), 1.95 (m, 2H), 1.81 (m, 2H), 1.73 (m, 2H), 1.60 (m, 4H), 1.49 (m, 2H), 0.98 (t, *J* = 7.4 Hz, 3H).^13^C (CD~3~OD, 100 MHz), δ 160.1, 154.8, 151.1, 147.6, 99.6, 69.2, 61.9, 58.2, 53.5, 45.3, 34.8, 32.0, 30.5, 28.5, 22.1, 20.2 14.2. HRMS calculated for C~19~H~32~N~6~O~3~ \[M + H\]^+^ 393.2614; found 393.2626.

### 6-Amino-2-butoxy-9-\[(1-hydroxyhexyl-4-piperidinyl)methyl\]-7,9-dihydro-8*H*-purin-8-one Hydrochloride **6c** {#sec4.3.35}

The title compound was prepared as a white solid in an 89% yield by acidic deprotection of **14c**, according to the general acidic deprotection procedure. ^1^H NMR (CD~3~OD, 400 MHz), δ 4.26 (t, *J* = 6.5 Hz, 2H), 3.77 (d, *J* = 6.7 Hz, 2H), 3.55 (t, *J* = 6.4 Hz, 4H), 3.07 (t, *J* = 8.1 Hz, 2H), 2.94 (m, 1H), 2.20 (m, 1H), 1.95 (m, 2H), 1.73 (m, 4H), 1.38--1.66 (m, 10H), 0.98 (t, *J* = 7.4 Hz, 3H).^13^C (CD~3~OD, 100 MHz), δ 162.1, 155.1, 151.0, 149.9, 99.7, 68.0, 62.6, 58.2, 53.5, 49.5, 49.3, 45.0, 34.7, 33.2, 32.3, 28.4, 27.4, 26.4, 25.2, 20.3, 14.2. HRMS calculated for C~21~H~36~N~6~O~3~ \[M + H\]^+^ 421.2927; found 421.2926.

### 6-Amino-2-butoxy-9-\[(1-aminoethyl-4-piperidinyl)methyl\]-7,9-dihydro-8*H*-purin-8-one Hydrochloride **6d** {#sec4.3.36}

The title compound was prepared as a white solid in a 74% yield by acidic deprotection of **14d**, according to the general acidic deprotection procedure. ^1^H NMR (D~2~O, 400 MHz), δ 4.23 (t, *J* = 6.5 Hz, 2H), 3.66 (m, 2H), 3.16 (m, 4H), 2.89 (m, 2H), 2.43 (m, 2H), 1.99 (m, 1H), 1.74 (m, 2H), 1.67 (m, 2H), 1.40 (m, 4H), 0.90 (t, *J* = 7.4 Hz, 3H). ^13^C (CD~3~OD, 100 MHz), δ 161.5, 154.1, 150.9, 149.1, 99.3, 67.3, 55.7, 53.9, 49.9, 37.2, 36.1, 31.9, 30.5, 20.1, 15.1. HRMS calculated for C~17~H~29~N~7~O~2~ \[M + H\]^+^ 364.2462; found 364.2462.

### 6-Amino-2-butoxy-9-(4-piperazinyl)ethyl-7,9-dihydro-8*H*-purin-8-one Hydrochloride **7a** {#sec4.3.37}

The title compound was prepared as a white solid in a 77% yield by acidic deprotection of **16a**, according to the general acidic deprotection procedure. ^1^H NMR (CD~3~OD, 400 MHz), δ 4.26 (t, *J* = 6.5 Hz, 2H), 3.96 (t, *J* = 5.9 Hz, 2H), 3.11 (m, 4H), 2.78 (m, 6H), 1.73 (m, 2H), 1.48 (m, 2H), 0.98 (t, *J* = 7.4 Hz, 3H). ^13^C (CD~3~OD, 100 MHz), δ 161.5, 155.1, 150.3, 149.5, 100.0, 68.4, 55.5, 50.1, 44.0, 37.4, 31.3, 19.6, 14.0. HRMS calculated for C~15~H~25~N~7~O~2~ \[M + H\]^+^ 336.2136; found 336.2137.

### 6-Amino-2-butoxy-9-(4-piperazinyl)butyl)-7,9-dihydro-8*H*-purin-8-one Hydrochloride **7b** {#sec4.3.38}

The title compound was prepared as an off-white solid in a 92% yield by acidic deprotection of **16b**, according to the general acidic deprotection procedure. ^1^H NMR (D~2~O, 400 MHz), δ 4.52 (t, *J* = 6.4 Hz, 2H), 3.96 (m, 2H), 3.66 (m, 6H), 3.35 (m, 4H), 1.89 (m, 4H), 1.82 (m, 2H), 1.53 (m, 2H), 1.00 (t, *J* = 7.4 Hz, 3H). ^13^C (CDCl~3~/CD~3~OD, 100 MHz), δ 155.3, 152.9, 149.7, 142.5, 98.1, 69.7, 56.3, 48.1, 40.5, 39.1, 30.2, 25.0, 20.5, 18.6, 12.7. HRMS calculated for C~17~H~29~N~7~O~2~ \[M + H\]^+^ 364.2461; found 364.2463.

### 6-Amino-2-butoxy-9-(4-aminopiperidinyl)ethyl-7,9-dihydro-8*H*-purin-8-one Hydrochloride **8a** {#sec4.3.39}

The title compound was prepared as an off-white solid in a 96% yield by acidic deprotection of **18a**, according to the general acidic deprotection procedure. ^1^H NMR (D~2~O/CD~3~OD, 400 MHz), δ 4.27 (t, *J* = 6.5 Hz, 2H), 3.96 (t, *J* = 6.2 Hz, 2H), 3.12 (m, 2H), 3.05 (m, 1H), 2.75 (t, *J* = 6.2 Hz, 2H), 2.15 (m, 2H), 1.93 (m, 2H), 1.74 (m, 2H), 1.44--1.58 (m, 4H), 0.98 (t, *J* = 7.4 Hz, 3H). ^13^C (D~2~O/CD~3~OD, 100 MHz), δ 157.6, 154.5, 151.0, 145.0, 100.2, 70.8, 52.1, 46.7, 36.1, 31.7, 28.4, 20.1, 14.1. HRMS calculated for C~16~H~27~N~7~O~2~ \[M + H\]^+^ 350.2305; found 350.2305.

### 6-Amino-2-butoxy-9-(4-hydroxypiperidinyl)ethyl-7,9-dihydro-8*H*-purin-8-one Hydrochloride **8b** {#sec4.3.40}

The title compound was prepared as a white solid in a 98% yield by acidic deprotection of **18b**, according to the general acidic deprotection procedure. ^1^H NMR (CD~3~OD, 400 MHz), δ 4.27 (t, *J* = 6.5 Hz, 2H), 4.22 (t, *J* = 5.5 Hz, 2H), 3.96 (m, 1H), 3.43--3.57 (m, 4H), 3.31 (m, 2H, obscured by methanol), 2.07 (m, 2H), 1.84 (m, 2H), 1.73 (m, 2H), 1.49 (m, 2H), 0.98 (t, *J* = 7.4 Hz, 3H). ^13^C (CD~3~OD, 100 MHz), δ 162.0, 154.9, 150.6, 150.2, 100.0, 68.2, 56.6, 36.2, 32.2, 20.3, 14.2. HRMS calculated for C~16~H~26~N~6~O~3~ \[M + H\]^+^ 351.2145; found 351.2142.

Biology {#sec4.4}
-------

### hTLR7/8 NFκB Reporter Assay {#sec4.4.1}

Human embryonic kidney (HEK) 293 cells expressing human TLR7 or TLR8 and an NFκB-responsive SEAP reporter gene were obtained from Novus Biologicals (Littleton, CO) or Invivogen (San Diego, CA), respectively. These cells were maintained in culture media of Dulbecco's modified Eagle's medium (HyCone, Logan, UT), 10% heat-inactivated FBS (Corning, Manassas, VA), and selection antibiotics (Invivogen). HEK293 cells were stimulated for 24 h with increasing concentrations of the indicated compounds, and culture supernatants were analyzed for NFκB activation using the colorimetric SEAP detection kit QuantBlue (Invivogen). Values are expressed as fold change in OD~650~ over vehicle-only treated samples, and EC~50~s are mean values and standard deviation of three or four independent experiments. EC~50~s were calculated by nonlinear curve fitting (four parameters) after generating dose--response curves in GraphPad Prism 7.03.

### Measurement of Cytokines from hPBMCs {#sec4.4.2}

Human whole blood was collected from normal healthy donors at the University of Montana (Missoula, MT) using an institutional review board approved protocol. All donors provided written informed consent prior to participation. Peripheral blood mononuclear cells (PBMCs) were isolated via a Ficoll Hypaque 1.077 gradient separation and cultured at 0.5 × 10^6^ cells/well in 96-well tissue culture plates with RPMI-1640 media (HyCone, Logan, UT), Pen/Strep/Glutamine (HyCone, Logan, UT), and 10% heat-inactivated FBS (Corning, Manassas, VA). Human PBMCs were stimulated for 24 h with increasing concentrations of the indicated compounds. Culture supernatants were analyzed for TNFα and IFNα levels using human TNFα DuoSet (R) ELISA kit (R&D Systems, Minneapolis, MN) and human IFNα VeriKine ELISA kit (Pestka Biomedical Laboratories, Inc., Piscataway, NJ).

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.9b02138](http://pubs.acs.org/doi/abs/10.1021/acsomega.9b02138).Characterization data (^1^H NMR spectra for compounds **2**--**4**, **6**--**8**, **10**--**12**, and **14**--**18** and ^13^C NMR spectra for compounds **2**--**4** and **6**--**8**); TLR7/8 agonistic activity and cytokine induction for compounds **1**--**8** ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02138/suppl_file/ao9b02138_si_001.pdf))

Supplementary Material
======================

###### 

ao9b02138_si_001.pdf

^∥^ Pfizer, 7000 Portage Road, Kalamazoo, Michigan 49001, United States (S.C.M.).

^⊥^ Transcenta, 51 Sawyer Road, Rockville, Waltham, Massachusetts 02453, United States (Y.L.).

D.A.J., H.G.B., and J.T.E. contributed to the conception and design; and H.G.B., L.S.B., S.C.M., M.T.L., V.C., Y.L., and J.T.E. to data acquisition and/or analysis and interpretation of data. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

This work was supported, in part, by the National Institute of Allergy and Infectious Diseases (NIAIDs) under contract HHSN272200900036C (to Corixa Corporation d/b/a GlaxoSmithKline Biologicals SA, novated to the University of Montana) and by the Center for Translational Medicine at the University of Montana. Any opinions, findings, conclusions, or recommendations expressed in this article are those of the authors and do not necessarily reflect the views of the NIAIDs.

The authors declare the following competing financial interest(s): All authors were employees of the GSK group of companies at the time when the TLR7/8 agonists described here were first prepared and tested. HB, LB, ML, VC and JE became employees of the University of Montana where additional compound synthesis/characterization and in vitro testing were completed.

The authors thank Lois Walsh for the formulation of the compounds described in this study and GlaxoSmithKline Biologicals SA where the compounds were first prepared and tested under NIAID contract HHSN272200900036C.
